Lincomycin vs Azithromycin (RCT)

Hospitalized patients

FOREST PLOTS -2020-10-02

Studies description

Trial *
Publication Guvenmez O, J Popul Ther Clin Ph (2020) (published paper)
Dates: 2020-02-01 to 2020-03-31
Funding: No specific funding (The authors declare that there is no financial support for this article.)
Conflict of interest: No

Methods
RCT
Blinding:
Location : Single center / Turkey
Follow-up duration (days): 6
Inclusion criteria
  • (1) an age range of 30–80 years,
    (2) real-time RT-PCR documented SARS-CoV-2 carriage in the bronchoalveolar lavage fluid,
    (3) findings of pneumonia in chest CT compatible with COVID-19,
    (4) no need for ventilatory assistance and
    (5) not using any medications other than LINCOCIN® and AZITRO®
Exclusion criteria
  • Pregnant patients and patients with known allergy to LINCOCIN® and AZITRO®
Interventions
Treatment
Lincomycin
600 mg IV twice a day for 5 days

Azithromycin
500 mg orally for the first day, followed by 250 mg orally for the next 4 days
Control
Participants
Randomized
participants :
Lincomycin =12
Azithromycin=12
Characteristics of participants
N= 24
Mean age : NR
15 males
Severity : Mild: n=0 / Moderate: n=24 / Severe: n=0 Critical: n=0
Primary outcome
In the register
NR
In the report
NR
Documents
avalaible

Protocol

NR

Statistical plan

NR

Data-sharing willing stated in the publication:

Yes
Risk of bias
Overall
The overall risk of bias reported in the table corresponds to the highest risk of bias for the outcomes assessed for the systematic review
Some concerns
General comment Only the published article was used in data extraction and risk of bias assessment. No primary outcome was specified in the report although one outcome measure was reported in detail (negative RT-PCR) and can be assumed to be the primary outcome. No study protocol or registration was available, so we cannot determine whether or not the target sample size was achieved, there was a change from the trial registration in the intervention and control treatment or the primary and secondary outcomes. Very few baseline characteristics were reported, and no details on comorbidities were reported.